Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals' stock price has increased by 27.21% over the past six months, with a 52-week range of $19.05 to $26.58. Key events include stronger-than-expected Q3 2025 earnings, which led to a share increase, and a 28.3% year-over-year revenue growth in Q4 2024. There have been instances of insider selling, including the Lead Independent Director exercising options and selling US$351k worth of stock in December 2025, and the Executive VP & Chief Commercial Officer notifying of an intention to sell stock in November 2025. In October 2025, the company announced a $200 million equity buyback program. As of February 5, 2026, the stock has an average rating of "Buy" from eight research firms, with an average 12-month price objective of $33.20.

Specific information regarding demand seasonality for Catalyst Pharmaceuticals' products was not explicitly found. Demand for pharmaceutical products, especially those treating rare and chronic diseases, is typically driven by ongoing medical need rather than seasonal consumer patterns. Factors such as diagnosis rates, prescription renewal cycles, and patient adherence could indirectly influence demand over time. The company's focus on rare diseases suggests a relatively stable demand profile, as these conditions require continuous treatment regardless of the season.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. The company operates within the Health Technology sector, specifically in the Pharmaceuticals: Major or Biotechnology industry. Its major products include Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, Ruzurgi for pediatric LEMS patients, Fycompa for partial-onset seizures and primary generalized tonic-clonic seizures, and AGAMREE for Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Catalyst Pharmaceuticals has a strong presence in the United States, which is central to its commercial strategy. The company is exploring opportunities to expand globally. Firdapse is available in Canada and Japan through a sub-licensee. AGAMREE has been accepted by Health Canada for a New Drug Submission with Priority Review, potentially becoming the first approved DMD treatment in Canada by the end of 2025.

Catalyst Pharmaceuticals has a positive brand reputation, particularly in the rare disease biopharmaceutical industry. The company was recognized on Forbes' 2026 List of America's Most Successful Small-Cap Companies. Analysts generally have a favorable view, with a consensus "Buy" rating and a predicted upside of 35.84% based on 12-month stock forecasts. The company emphasizes its commitment to patient care and accessibility, providing support services to ensure patients receive necessary care.

Catalyst Pharmaceuticals has a diverse ownership structure, with institutional investors holding a significant portion (82%) of the business, totaling 123,972,701 shares held by 656 institutional owners and shareholders. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., iShares Core S&P Small-Cap ETF (IJR), State Street Corp., Deerfield Management Company, L.p. (series C), Renaissance Technologies Llc, Fundsmith LLP, Geode Capital Management, Llc, and iShares Russell 2000 ETF (IWM). Major individual owners (insiders) include Patrick J. McEnany, Richard J. Daly, Steve Miller, Hubert E. Huckel, Brian Elsbernd, and Jeffrey Del Carmen.